公开(公告)号：KR1020120111771A

公开(公告)日：2012-10-11

申请号：KR1020110027789

申请日：2011-03-28

Applicant: 동화약품주식회사

Inventor： 장환봉 ,  윤주병 ,  이현용 ,  최현식 ,  이형복

IPC: A61K36/605 ,  A61K31/36 ,  A61P3/10

CPC classification number: A61K31/352 ,  A23L33/10 ,  A61K31/05 ,  A61K31/353

Abstract: PURPOSE: A final glycosylation product inhibitor or health functional food is provided to suppress development of diabetic complication. CONSTITUTION: A final glycosylation product inhibitor which suppresses the development of diabetes complication contains mulberrofuran G isolated from Morus bark, mulberrofuran K, kuwanon G, kuwanon Z, oxyresveratrol, 2',4',5,7-tetrahydroxyflavanone, morusignin L, or dihydromorin as an active ingredient. The diabetic complication includes diabetic splenocyte nephritis, diabetic retinopathy or diabetic splenocyte neuropathic disease. [Reference numerals] (1) Normal group(-20°C); (10) Morusignin-L; (11) Dihydromorin; (2) Control group(37°C); (3) Pyridoxamine(positive control group); (4) Mulberrofuran-G; (5) Mulberrofuran-K; (6) Kuwanon-G; (7) Kuwanon-Z; (8) 2'.4'.5.7-tetrahydroxyflavanone; (9) Oxyresveratrol; (AA) Anti-AGEs antibody; (BB) Anti-CML antibody; (CC) Ponseau S staining

Abstract translation: 目的：提供最终的糖基化产物抑制剂或保健功能食品来抑制糖尿病并发症的发展。 构成：抑制糖尿病并发症发展的最终糖基化产物抑制剂含有从桑树皮，多杀龙furan酮K，kuwanon G，kuwanon Z，氧基白藜芦醇，2'，4'，5,7-四羟基黄烷酮，morusignin L或二氢肌醇 作为活性成分。 糖尿病并发症包括糖尿病性脾细胞性肾炎，糖尿病性视网膜病变或糖尿病脾细胞性神经病变。 （附图标记）（1）正常组（-20℃）; （10）Morusignin-L; （11）二氢吗啉; （2）对照组（37℃）; （3）吡哆胺（阳性对照组）; （4）芒果呋喃-G; （5）甲基呋喃-K; （6）Kuwanon-G; （7）Kuwanon-Z; （8）2'4'5.7-四羟基黄烷酮; （9）氧化维生素; （AA）抗AGEs抗体; （BB）抗CML抗体; （CC）Ponseau S染色

公开(公告)号：KR1020060049859A

公开(公告)日：2006-05-19

申请号：KR1020050060437

申请日：2005-07-05

Applicant: 동화약품주식회사

Inventor： 이진수 ,  안석훈 ,  진영구 ,  박재훈 ,  신동혁 ,  조은희 ,  장환봉 ,  정용호

IPC: C07D277/24

CPC classification number: C07D277/24

Abstract: 본 발명은 N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘의 개선된 제조방법에 관한 것이다.
벤즈아미딘

公开(公告)号：KR1020050100890A

公开(公告)日：2005-10-20

申请号：KR1020040026104

申请日：2004-04-16

Applicant: 동화약품주식회사

Inventor： 정용호 ,  임문정 ,  노양국 ,  장환봉 ,  성희진 ,  백남현 ,  성승규

IPC: A61K36/254 ,  A61K36/82 ,  A61P1/16 ,  A61P39/02

Abstract: 본 발명은 오가피 및 녹차 추출물을 유효성분으로 함유하는 숙취해소 및 간장 보호를 위한 조성물에 관한 것으로서, 본 발명의 오가피 및 녹차 추출물은 인체에 부작용이 없으면서 알코올의 분해 작용 및 간장 보호 효과가 탁월하므로, 이를 유효성분으로 함유하는 조성물은 숙취해소 및 간장 보호를 위한 의약품 및 건강기능식품으로써 유용하게 이용될 수 있다.

公开(公告)号：KR1020010048569A

公开(公告)日：2001-06-15

申请号：KR1019990053294

申请日：1999-11-27

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  이상욱 ,  김남두 ,  박용균 ,  이근형 ,  김종우 ,  박상진 ,  박희정 ,  장환봉

IPC: C07D239/10

Abstract: PURPOSE: Novel 5-pyrimidinecarboxamide derivatives inhibiting the growth of HBV and HIV, a pharmaceutically acceptable salt thereof, a preparation thereof and an antiviral composition containing the compound as an effective component are provided, which show less adverse effects and can be effectively used for prevention and treatment of HBV and HIV. CONSTITUTION: The novel 5-pyrimidinecarboxamide derivatives of formula 1 are prepared by the following processes: 4-chloro-2-methylthio-5-pyrimidinecarboxylic acid ethyl ester of formula 2 and 5-aminoindazole or 6-aminoindazole of the formula; R2-NH2 are reacted in the presence of a base to produce 5-pyrimidine carboxylic acid ethyl ester derivative of formula 4; and the obtained 5-pyrimidine carboxylic acid ethyl ester derivative is reacted with an amine compound(R1-NH2). In formula, R1 is H, C1-4 straight or branched alkyl, C3-6 cycloalkyl or C2-3 hydroxyalkyl; R2 is indazole-5-yl or indazole-6-yl.

Abstract translation: 目的：提供抑制HBV和HIV生长的新型5-嘧啶甲酰胺衍生物，其药学上可接受的盐，其制备方法和含有该化合物作为有效成分的抗病毒组合物，其效果较差，可有效用于预防 以及治疗HBV和HIV。 构型：式1的新型5-嘧啶甲酰胺衍生物通过以下方法制备：式2的4-氯-2-甲硫基-5-嘧啶羧酸乙酯和下式的5-氨基吲唑或6-氨基吲唑; R2-NH2在碱的存在下反应，生成式4的5-嘧啶羧酸乙酯衍生物; 并将所得的5-嘧啶羧酸乙酯衍生物与胺化合物（R1-NH2）反应。 在式中，R 1是H，C 1-4直链或支链烷基，C 3-6环烷基或C 2-3羟基烷基; R2是吲唑-5-基或吲唑-6-基。

公开(公告)号：KR1020070081294A

公开(公告)日：2007-08-16

申请号：KR1020060013167

申请日：2006-02-10

Applicant: 동화약품주식회사

Inventor： 유제만 ,  임문정 ,  노양국 ,  오성준 ,  이현용 ,  장환봉 ,  황연하 ,  이정욱

IPC: A61K31/341 ,  A61K31/56 ,  A61K36/47 ,  A61P19/10

Abstract: A composition for preventing and treating osteoporosis comprising terpenoids isolated from Euphorbia kansui or the extracts thereof is provided to inhibit bone absorption of osteoclasts without side effects. The composition for preventing and treating osteoporosis comprises kansuinine A represented by the formula(1) and gamma-euphorbol represented by the formula(2) or the extracts thereof. The kansuinine A represented by the formula(1) and gamma-euphorbol represented by the formula(2) are isolated by extracting and concentrating Euphorbia kansui with methanol, suspending the concentrated extract of Euphorbia kansui in water, and adding nucleic acid into the suspension to separate a nucleic acid layer, adding methylene chloride into a water layer obtained by separating the nucleic acid layer to obtain a methylene chloride fraction, and subjecting the methylene chloride fraction to chromatography.

Abstract translation: 提供了用于预防和治疗包括从大戟属分离的萜类化合物或其提取物的骨质疏松症的组合物，以抑制破骨细胞的骨吸收而没有副作用。 用于预防和治疗骨质疏松症的组合物包括由式（1）表示的苦参碱A和由式（2）表示的γ-高效药或其提取物。 由式（1）表示的甘露宁A和由式（2）表示的γ-高效酚通过用甲醇萃取浓缩大戟甘油，将浓缩的大戟属浓缩提取物悬浮于水中，并将核酸加入到悬浮液中 分离核酸层，将二氯甲烷加入到通过分离核酸层获得的水层中，得到二氯甲烷部分，并将二氯甲烷部分进行色谱分离。

公开(公告)号：KR100566188B1

公开(公告)日：2006-03-29

申请号：KR1019990053294

申请日：1999-11-27

Applicant: 동화약품주식회사

Inventor： 윤성준 ,  이상욱 ,  김남두 ,  박용균 ,  이근형 ,  김종우 ,  박상진 ,  박희정 ,  장환봉

IPC: C07D239/10

Abstract: 본 발명은 신규의 5-피리미딘카르복스아미드 유도체, 그의 제조방법 및 그를 포함하는 약학적 조성물에 관한 것으로서, 구체적으로 비핵산계 화합물인 하기 화학식 1로 표시되는 5-피리미딘카르복스아미드 유도체는 HBV (Hepatitis B Virus) 증식 뿐만 아니라 HIV (Human Immunodeficiency Virus) 증식을 억제하는 효과를 나타내므로 B형 간염 및 후천성 면역 결핍증의 치료제 및 예방제로서 유용하게 사용될 수 있다.

상기 식에서, R
1 및 R
2 는 명세서에 기재된 바와 같다.

公开(公告)号：KR1020000031736A

公开(公告)日：2000-06-05

申请号：KR1019980047919

申请日：1998-11-10

Applicant: 양철학 ,  동화약품주식회사

Inventor： 윤성준 ,  이덕근 ,  함은령 ,  신동혁 ,  장환봉 ,  박세연 ,  양철학

IPC: A61K31/352 ,  A61K36/9064 ,  A61P35/00

CPC classification number: A61K31/352 ,  A61K36/9064 ,  A61K2236/35 ,  A61K2236/51

Abstract: PURPOSE: An Alpinia katsumadai extract having anti-cancer activity is provided which contains 7,8-dihydroxyflavanone. CONSTITUTION: 7,8-dihydroxyflavanone inhibits the formation of Jun-Pos dimmer or the binding of Jun-Pos dimmer to DNA, so that it prevents the growth of cancer cells. The Alpinia katsumadai extract is obtained by organic solvent such as ether, benzene, methanol, ethanol, butanol, chloroform, methylene chloride, ethyl acetate, and hexane. 7,8-dihydroxyflavanone is purified by the following steps of: 1)the extraction of Alpinia katsumadai with ether and benzene; 2)the application of the Alpinia katsumadai extract to silica gel chromatography using mixture of hexane and ethyl acetate(9: 1, 4: 1, 2: 1); 3)the crystallization of the 23rd fraction out of 60 fractions.

Abstract translation: 目的：提供含有7,8-二羟基黄烷酮的具有抗癌活性的抗坏血酸提取物。 构成：7,8-二羟基黄酮抑制Jun-Pos二聚体的形成或Jun-Pos二聚体与DNA的结合，从而防止癌细胞的生长。 通过有机溶剂如乙醚，苯，甲醇，乙醇，丁醇，氯仿，二氯甲烷，乙酸乙酯和己烷得到高山ai ai提取物。 7,8-二羟基黄酮通过以下步骤纯化：1）用乙醚和苯提取枸杞子; 2）使用己烷和乙酸乙酯（9:1,4:1,2:1）的混合物，将Alpinia katsumadai提取物应用于硅胶色谱法; 3）第60部分中第23部分的结晶。